Accera

BROOMFIELD, Colorado - - Study to be presented at the 2009 International Conference on Alzheimer's Disease Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, today announced further evidence for genetic interactions impacting the efficacy of the ketogenic compound AC-1202 (Axona(TM)) in Alzheimer's disease.

BROOMFIELD, Colorado - New Business Spin-off to Focus on Drug Development for Neurological Conditions Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, announced today the formation of Neuera Pharmaceuticals, Inc., a drug development company.